{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:57:07Z","timestamp":1793145427644,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100005349","name":"Socialstyrelsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019040","name":"Respicardia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019040","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsradet","doi-asserted-by":"publisher","award":["523-2014-2336"],"award-info":[{"award-number":["523-2014-2336"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008497","name":"Boston Scientific Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008497","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006484","name":"Vifor Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006484","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014941","name":"Cytokinetics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014941","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009240","name":"Sveriges Kommuner och Landsting","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009240","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["FS\/18\/14\/33330"],"award-info":[{"award-number":["FS\/18\/14\/33330"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["RE\/18\/6\/34217"],"award-info":[{"award-number":["RE\/18\/6\/34217"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","award":["20180899"],"award-info":[{"award-number":["20180899"]}],"id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003793","name":"Hj\u00e4rt-Lungfonden","doi-asserted-by":"publisher","award":["20190310"],"award-info":[{"award-number":["20190310"]}],"id":[{"id":"10.13039\/501100003793","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003793","name":"Hj\u00e4rt-Lungfonden","doi-asserted-by":"publisher","award":["20150557"],"award-info":[{"award-number":["20150557"]}],"id":[{"id":"10.13039\/501100003793","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institutet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004348","name":"Stockholms L\u00e4ns Landsting","doi-asserted-by":"publisher","award":["20190525"],"award-info":[{"award-number":["20190525"]}],"id":[{"id":"10.13039\/501100004348","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004348","name":"Stockholms L\u00e4ns Landsting","doi-asserted-by":"publisher","award":["20170112"],"award-info":[{"award-number":["20170112"]}],"id":[{"id":"10.13039\/501100004348","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Heart Failure"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.jchf.2022.04.006","type":"journal-article","created":{"date-parts":[[2022,5,30]],"date-time":"2022-05-30T14:00:31Z","timestamp":1653919231000},"page":"380-392","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Apparent Treatment-Resistant Hypertension Across the Spectrum of Heart\u00a0Failure Phenotypes in the Swedish\u00a0HF Registry"],"prefix":"10.1016","volume":"10","author":[{"given":"Alice M.","family":"Jackson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Benson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7732-0887","authenticated-orcid":false,"given":"Gianluigi","family":"Savarese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4142-2416","authenticated-orcid":false,"given":"Camilla","family":"Hage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pardeep S.","family":"Jhund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark C.","family":"Petrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Dahlstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6317-3975","authenticated-orcid":false,"given":"John J.V.","family":"McMurray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars H.","family":"Lund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchf.2022.04.006_bib1","first-page":"471","article-title":"Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction: rationale and design of the PARAGON-HF trial","volume":"5","author":"Solomon","year":"2017","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jchf.2022.04.006_bib2","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2022.04.006_bib3","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2022.04.006_bib4","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1161\/HYP.0000000000000084","article-title":"Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association","volume":"72","author":"Carey","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.jchf.2022.04.006_bib5","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1161\/CIRCULATIONAHA.111.068064","article-title":"Incidence and prognosis of resistant hypertension in hypertensive patients","volume":"125","author":"Daugherty","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2022.04.006_bib6","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1161\/HYPERTENSIONAHA.114.03850","article-title":"Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"64","author":"Muntner","year":"2014","journal-title":"Hypertens (Dallas, Tex 1979)"},{"key":"10.1016\/j.jchf.2022.04.006_bib7","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1093\/eurheartj\/ehab499","article-title":"Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction","volume":"42","author":"Jackson","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2022.04.006_bib8","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/ajh\/hpx210","article-title":"Spironolactone and resistant hypertension in heart failure with preserved ejection fraction","volume":"31","author":"Rossignol","year":"2018","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.jchf.2022.04.006_bib9","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/eurjhf\/hfp175","article-title":"Heart failure registry: a valuable tool for improving the management of patients with heart failure","volume":"12","author":"Jonsson","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2022.04.006_bib10","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/03009734.2018.1490831","article-title":"The Swedish Heart\u00a0Failure Registry: a living, ongoing quality assurance and research in heart failure","volume":"124","author":"Savarese","year":"2019","journal-title":"Ups J Med Sci"},{"key":"10.1016\/j.jchf.2022.04.006_bib12","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.jchf.2022.04.006_bib13","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2022.04.006_bib14","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41569-021-00605-5","article-title":"Heart failure with mid-range or mildly reduced ejection fraction","volume":"19","author":"Savarese","year":"2022","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jchf.2022.04.006_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0114958","article-title":"The prevalence and prognosis of resistant hypertension in patients with heart failure","volume":"9","author":"Jin","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jchf.2022.04.006_bib16","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s40292-018-0268-x","article-title":"Prevalence and comorbidities of resistant hypertension: a collaborative population-based observational study","volume":"25","author":"Romano","year":"2018","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"10.1016\/j.jchf.2022.04.006_bib17","article-title":"Resistant hypertension, time-updated blood pressure values and renal outcome in type 2 diabetes mellitus","volume":"6","author":"Viazzi","year":"2017","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jchf.2022.04.006_bib18","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/ehjcvp\/pvz057","article-title":"Resistant hypertension: new insights and therapeutic perspectives","volume":"6","author":"Ruilope","year":"2020","journal-title":"Eur Hear J Cardiovasc Pharmacother"},{"key":"10.1016\/j.jchf.2022.04.006_bib19","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1159\/000321688","article-title":"Adherence to antihypertensive agents and blood pressure control in chronic kidney disease","volume":"32","author":"Schmitt","year":"2010","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.jchf.2022.04.006_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11892-014-0516-y","article-title":"Resistant hypertension in diabetes mellitus","volume":"14","author":"Bayliss","year":"2014","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.jchf.2022.04.006_bib21","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1161\/HYPERTENSIONAHA.111.190223","article-title":"Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction","volume":"59","author":"Briones","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.jchf.2022.04.006_bib22","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1038\/aps.2018.40","article-title":"Leptin, cardiovascular diseases and type 2 diabetes mellitus","volume":"39","author":"Katsiki","year":"2018","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.jchf.2022.04.006_bib23","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/jch.12049","article-title":"Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment","volume":"15","author":"Landsberg","year":"2013","journal-title":"J\u00a0Clin Hypertens"},{"key":"10.1016\/j.jchf.2022.04.006_bib24","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s10741-021-10086-w","article-title":"Prognostic value of blood pressure in ambulatory heart failure: a meta-analysis and systematic review. Ambulatory blood pressure predicts heart failure prognosis","volume":"27","author":"Lee","year":"2022","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.jchf.2022.04.006_bib25","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11906-017-0709-2","article-title":"Current perspectives on systemic hypertension in heart failure with preserved ejection fraction","volume":"19","author":"Tam","year":"2017","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.jchf.2022.04.006_bib26","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1093\/eurheartj\/ehl193","article-title":"EuroHeart\u00a0Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population","volume":"27","author":"Nieminen","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2022.04.006_bib27","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1001\/jama.296.18.2217","article-title":"Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure","volume":"296","author":"Gheorghiade","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.jchf.2022.04.006_bib28","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1056\/NEJM200101043440103","article-title":"The pathogenesis of acute pulmonary edema associated with hypertension","volume":"344","author":"Gandhi","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2022.04.006_bib29","article-title":"Spironolactone use and improved outcomes in patients with heart failure with preserved ejection fraction with resistant hypertension","volume":"9","author":"Tsujimoto","year":"2020","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jchf.2022.04.006_bib30","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jamacardio.2017.5365","article-title":"Systolic blood pressure and outcomes in patients with heart failure with preserved ejection fraction","volume":"3","author":"Tsimploulis","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jchf.2022.04.006_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0253999","article-title":"Admission systolic blood pressure as a prognostic predictor of acute decompensated heart failure: a report from the KCHF registry","volume":"16","author":"Kawase","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.jchf.2022.04.006_bib32","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1161\/HYPERTENSIONAHA.119.13069","article-title":"Early onset hypertension is associated with hypertensive end-organ damage already by midlife","volume":"74","author":"Suvila","year":"2019","journal-title":"Hypertension"}],"container-title":["JACC: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177922002554?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177922002554?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T13:47:05Z","timestamp":1778852825000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213177922002554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S2213177922002554"],"URL":"https:\/\/doi.org\/10.1016\/j.jchf.2022.04.006","relation":{},"ISSN":["2213-1779"],"issn-type":[{"value":"2213-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Apparent Treatment-Resistant Hypertension Across the Spectrum of Heart\u00a0Failure Phenotypes in the Swedish\u00a0HF Registry","name":"articletitle","label":"Article Title"},{"value":"JACC: Heart Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2022.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}